相关实验视频

Updated: Jul 11, 2025

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

人类表皮生长因子受体-2 胃腺癌:扩大已知的目标治疗范围

Jane E Rogers¹, Kohei Yamashita², Matheus Sewastjanow-Silva²

¹Pharmacy Clinical Programs, U.T. M.D. Anderson Cancer Center, Houston, TX 77030, USA.

|November 14, 2023

概括

人类表皮生长因子受体-2 (HER2) 向疗法在胃癌中由于瘤异质性而表现出不同的有效性. 了解耐药性是开发新的针对HER2的治疗方法的关键.

科学领域:

在瘤学瘤学.
分子生物学分子生物学
胃肠病学胃肠病学

背景情况:

人类表皮生长因子受体-2 (HER2) 是癌症治疗中的关键标.
针对HER2的药物在各种瘤类型中表现出不一致的疗效.
胃腺癌 (GAC) 显示出显著的瘤内和瘤间HER2表达异质性.

研究的目的:

审查目前在GAC中针对HER2的治疗方法的现状.
检查 HER2 异质性和耐药性在 GAC 治疗中所带来的挑战.
讨论新兴疗法及其对 HER2 阳性 GACs 的潜在影响.

主要方法:

在GAC中对HER2向疗法的文献综述.
对针对HER2异质性和耐药性机制的研究进行分析.
对新型HER2导向药物的正在进行的临床研究的审查.

主要成果:

HER2表达异质性使GAC中的治疗决策和结果复杂化.
主要部位和转移部位之间HER2状态的不一致性会影响治疗反应.
特拉斯图祖马布德鲁克斯泰坎为耐火性HER2阳性高级GAC提供了一个新的选择.

结论:

更深入地了解HER2异质性和耐药性模式对于推进GAC治疗至关重要.
需要对新型HER2向性药物进行进一步的研究.
需要个性化治疗策略来克服HER2-阳性GACs治疗障碍.

关键词:

在ZW2525中使用.胃肠道的新生病.人类表皮生长因子受体-2 马尔盖图克西马巴的情况这就是特拉斯图祖马布 (trastuzumab).特拉斯图祖马布可以脱.

更多相关视频

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

相关概念视频

Mitogens and the Cell Cycle

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...